2019
DOI: 10.1245/s10434-019-07335-6
|View full text |Cite
|
Sign up to set email alerts
|

The Value of Commission on Cancer Accreditation: Improving Survival Outcomes by Enhancing Compliance with Quality Measures

Abstract: In the United States, colorectal cancer is the third leading cause of cancer-related deaths in men and women and the second combined leading cause of cancer deaths.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 18 publications
0
1
0
Order By: Relevance
“…The potential for misclassification of race, particularly among individuals who identify as AI/AN, is another inherent limitation of cancer registry data [ 38 ]. Although the quality standards on which CoC accreditation is predicated are widely considered to have a positive effect on patient outcomes and survival [ 39 ], other facility factors, such as operative volume, may also directly impact patient outcomes [ 40 ]. Further, even among patients treated at CoC-accredited facilities, equal access may not always translate to equal care, as some recent NCDB analyses have challenged the potential role of race on prostate cancer outcomes, while others have identified Black race, female sex, and other patient demographic factors as predictors of less timely therapy and poorer survival in bladder cancer [ 41 , 42 ].…”
Section: Discussionmentioning
confidence: 99%
“…The potential for misclassification of race, particularly among individuals who identify as AI/AN, is another inherent limitation of cancer registry data [ 38 ]. Although the quality standards on which CoC accreditation is predicated are widely considered to have a positive effect on patient outcomes and survival [ 39 ], other facility factors, such as operative volume, may also directly impact patient outcomes [ 40 ]. Further, even among patients treated at CoC-accredited facilities, equal access may not always translate to equal care, as some recent NCDB analyses have challenged the potential role of race on prostate cancer outcomes, while others have identified Black race, female sex, and other patient demographic factors as predictors of less timely therapy and poorer survival in bladder cancer [ 41 , 42 ].…”
Section: Discussionmentioning
confidence: 99%